A pioneering study led by Professor Ashok Venkitaraman from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore and Dr Mona Shehata from the University of Cambridge (UK) has uncovered vital insights into the distinct effects of BRCA2 mutations on breast tissue cells, shedding light on early breast cancer development in people with BRCA2 mutations.